课题基金 / 基金详情

项目摘要

项目成果

Anton Simeonov的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although the global health emergency posed by the Zika virus (ZIKV) outbreak associated with severe neonatal neurological conditions has subsided, the continued transmission of ZIKV in endemic regions remains. As such, there is maintained interest in elucidating and developing interventions against ZIKV, a arthropod-borne flavivirus. To identify small-molecule anti-Zika compounds, we screened a collection of 6,000 compounds, most derived from natural products, for their ability to block wild-type ZIKV infection. We used a viral cytopathic effect (CPE) inhibition assay conducted in Vero cells that was optimized and miniaturized to 1536-well format. Suitably active compounds identified from the primary assay were subjected to a panel of orthogonal assays using recombinant Zika viruses, one using a recombinant Renilla luciferase reporter assay, the other a novel mCherry reporter system. Six active molecules were further evaluated for their inhibitory effects against other flaviviruses. Lastly, we developed a novel viral pathogenicity model in a 3D-bioprinted retinal tissue to better replicate in vivo infections of targeted Zika tissues in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Compound for Targeted Treatment of CBF Leukemia
Profliing Assay for Redox Potential
Identification of Myc translation inhibitors
Trans-NIH RNAi Facility (TNRF)
海外基金